Dr Giulia Pasello speaks to ecancer about patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC from the AEGEAN trial.

In the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone in patients with resectable NSCLC.

This study shows that adding perioperative durvalumab to neoadjuvant chemotherapy maintains quality of life, functioning, and symptoms compared to neoadjuvant chemotherapy alone.

Together with the significant efficacy improvements and manageable adverse events profile, these results further support perioperative durvalumab as a new treatment option for patients with R-NSCLC.